The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
more yesterday and more today, must be some other share in "play" with this as a possible target
7+% today, not complaining but??
What is not to like is that we are leaving the EU so ANCR stands to lose all that business.
I've been buying gently in and then today it goes up 6%, what gives?
Company goes from strength to strength, good cash cow in the animal ID business, good pipeline of products with European markets now joining in. Sensible dividend policy, good cash generation what not to like?
mentioned by Richard Beddard in iii stable and profitable business
and the Sp drops, for a nice conservative share like this one, why would people sell?
Animalcare Group plc (AIM: ANCR), a leading supplier of veterinary medicines, announces results for the year ended 30 th June 2014. This year has seen a solid performance resulting in the Group being cash generative, debt free and adopting a clear strategy for growth. Looking very good.....excellent statement in November too.
we finally get above 155p and I get a note from someone in ADVFN that they are selling as this is the only share that seems to be behaving sensibly in this oil driven price fall
today for this illiquid share
"The Board is pleased to announce that trading in the first four months of the financial year is ahead of prior year and in line with management expectations. Our investment in the infrastructure of the business is starting to deliver returns, including positive results from key account management and our new telesales team. Our product development pipeline is progressing well against internal project management milestones. We announced on 15th October 2014, that the Board has proposed the payment of an increased final dividend of 4.0 pence per share, giving a total dividend for the year of 5.5 pence per share, representing a 3.8% increase on the prior year. Formal approval will be sought at the AGM today.
another recommendation from the broker of 245p. which would be an 80% premium.
Small revenue growth, inventory up by £1m+ or >30%. Cost of the board up again ~20%?. New Sales manager though 82% of revenue goes to 3 customers. Yet another Business Development Director, (every 2 years?) with the need for the department to grow. I love the way the office move was made into a positive thing rather than just the lease ran out. I guess we have to hope the Business Director gets someone to buy the company as the last two didn't Dechra's growth has been about the same in the last year What is good is how detailed the financial reporting is, almost as if it were a business advert, if Dechra bought it they could save roughly £500k on day one
Hadn't picked up James buying £1.35m back in May. Well done, just a steady holder for next 18 months
Good steady RNS, doing what they said they would (invest for the long term and protect the growth) still SP is very cheap and well below broker's rec
James Lambert bought a bunch of shares (£1.4M??) a few days back and today someone else traded another £1.3M
Small volumes (not that liquid) but prices all one way Dechra came in with good profits so ANCR, with no announced supply problems should come in on line if not slightly ahead. What would change the SP is if someone made an offer. Anyone?
silly season?
well two good days for very little volume trading, interesting to see what is causing this, any ideas?
Animalcare has traded in line with market expectations for the year. The year has seen continued growth, with revenues 11% ahead of the previous 12 months. Latest market statistics show sales of veterinary medicines for companion animals in the UK to be flat; therefore Animalcare's growth is well ahead of the general market. This trend of growth across the Group is reflected in overall underlying earnings in line with expectations. The performance of our core Licensed Veterinary Medicines group was particularly notable, with revenues up by 22% compared with the prior year. Revenues for the Companion Animal Identification group were down in the period as a result of continued competition in the market, however unit sales were slightly ahead of management expectations and revenues from related services derived from the microchip database continued to grow against the previous period. Our Animal Welfare group performed well, with revenues up during the period. The new product pipeline of licensed veterinary medicines has continued to deliver. Three new products were launched in the year and a fourth received its Marketing Authorisation in June, with the launch expected in the first half of the current financial year. In March, Animalcare completed its relocation to new premises in the York area smoothly with no disruption to business. The new premises offer a much improved and efficient working environment with significantly more capacity for future growth. The Group remains firmly on track with its stated strategy of investing in intellectual property protected products and services that will deliver future sustainable growth, supported by Animalcare's sound cash position.
Alstoe Animal Health, also in York, was bought today. So maybe that deflated the price a bit. Down 2.5%
Loss of Stephen is a waste of talent, I orignally expected his promotion would be release time to find aquisition (they have a big cash bundle) but clearly he has failed. The Strategy Director role is the companies usual way of phasing people out while they hunt for a new job. Even so Stephen may stumble across something interesting worth buying. Note that the Chair's main business (Icecream) is up for sale to private equity so maybe he is looking for a quieter life. What is the logical conclusion from all of this. I can only assume that they want to sell the business. Yipeee
Post-Close Trading Update & Notice of Results Animalcare, a leading supplier of veterinary medicines, announces that the Half Yearly Report for the six months ended 31st December 2012 will be released on Thursday 21st February 2013. In keeping with past practice, the Board issues the following trading update ahead of its publication, which confirms a strong first half in line with management expectations and a positive outlook for the full year to June 2013. Animalcare has separately announced today that Stephen Wildridge is stepping down as Group CEO and Dr Iain Menneer, currently MD of Animalcare Ltd, has been appointed as his replacement with immediate effect. Stephen will continue to serve on the board and as Executive Director of Strategy and Business Development until 31st October 2013. Trading update Trading from continuing operations in the first six months has been strong and is in line with market expectations. Animalcare management is pleased to report, in what it believes is a flat veterinary medicines market in the UK, an encouraging set of results for the first half of the financial year with total first half revenue approximately +13% higher than in the comparable period last year at c. £6.1m. Gross profit is performing well ahead of the comparable period, +16%. As announced earlier this month, the re-introduction of Buprecare ampoules marked a positive start to 2013. Sales of the single-use Buprecare ampoule will add to the strong sales of the Buprecare multi-dose vial launched just 10 months ago. The total market in the UK for each dosage form is estimated at between £1.5m and £1.8m after all discounts. Whilst Licensed Veterinary Medicines have continued the strong growth reported in recent years, the Companion Animal Identification product group has, as expected, recovered some of the ground lost during the previous financial year. The re-developed registration database has underpinned much of the progress for this product group. Strong cash generation has continued and the Company holds circa £2.9m of cash balances at 31st December 2012 (up from £2.3m as at 30th June 2012). Summary and Outlook Animalcare's performance in the first half of the financial year represents a solid start. The launch of Vitofyllin and the re-introduction of Buprecare ampoules have had a motivating influence across the business and we expect to build on these products during the second half. Prospects for the second half look positive with full year results to June 2013 expected to be in line with market expectations. The product development pipeline is on track and continues to deliver the new veterinary medicines that are the driver for growth of Animalcare. The focus of senior management on the pipeline will be maintained to ensure the short to medium-term projects remain on target. We expect to meet our target to launch four
Animalcare Group plc announces that Stephen Wildridge is stepping down from the position of Group CEO and will leave the Group by the end of October 2013. Dr. Iain Menneer, currently Managing Director of Animalcare Ltd, will take over as Group CEO with immediate effect. Until October Stephen will remain with the business as Director of Strategy and Business Development driving forward Animalcare's key product development programmes and assisting Iain with implementing the overall strategy for the Group. Stephen will continue as a board director of the Group until October 2013. Since joining Animalcare in 2003 Stephen has been the architect of the Group's successful development into one of the leading UK animal health companies. He leaves the business in a strong and healthy position well placed for its continued development and the Board would like to record its thanks to Stephen for all of his hard work and endeavour. Iain Menneer is ideally qualified to assume the role of CEO, having joined Animalcare Ltd in December 2003 since when he has held marketing and business development roles; notably working on the product development pipeline. Iain was promoted to the Board as Director of Marketing on 1st July 2011 and subsequently appointed Managing Director of Animalcare Limited on 12th March 2012.
worth noting that James (chair) bought 50,000 shares just before christmas showing confidence in the business good to see Buprecare supply started again just after new year after a long struggle, well done guys and nice to see the share price rise a day after the fiscal cliff issue made a step.